Director and research team for UTRGV South Texas Diabetes and Obesity Institute to be announced Monday

Breaking News
1505

Translate to Spanish or other 102 languages!

Mega Doctor News

- Advertisement -

Two news conferences will be held Monday morning to announce that Dr. Sarah Williams-Blangero, a nationally renowned genetics and infectious disease expert, will be the inaugural director of the UTRGV South Texas Diabetes and Obesity Institute.

In addition, Dr. Williams-Blangero, former chair of the department of genetics at the Texas Biomedical Research Institute in San Antonio, is bringing a 22-person team of expert researchers and support staff with her to UTRGV.

The first news conference will take place at 9 a.m. in Salon Cassia at UT Brownsville’s Main (formerly the Education and Business Complex) and will be webcast live at media.utb.edu/live.aspx. The second news conference will begin at 11:15 a.m. in UT Pan American’s University Ballroom and will be webcast live at UTPA.edu/LIVE.

- Advertisement -

Both events will include remarks from Dr. Williams-Blangero; Chancellor Francisco G. Cigarroa, M.D.; Guy Bailey, founding president of UT Rio Grande Valley; and Francisco Fernandez, M.D., founding dean of the UTRGV School of Medicine.

- Advertisement -
- Advertisement -

Latest news

- Advertisement -
Previous article
AWFC Foster Children’s Christmas Party Run Fundraiser A World For Children
Next article
Hispanics Must Promote Longer, Healthier Lives

More Articles

Embolism Treatment Developed at University of Michigan receives FDA clearance 

Patients with persistent blood clots require frequent medical interventions just to survive. Yet despite this critical need, there have been few advancements in how these patients are treated. 

FDA Approves Once-Weekly Generic Hormone Therapy Patch for Women

The U.S. Food and Drug Administration approved the first generic of Climara Pro (estradiol and levonorgestrel transdermal system, 0.045 mg per day/0.015 mg), a transdermal hormone therapy patch for women with an intact uterus applied once a week. The approval aligns with FDA’s Public Health Pillar: Increasing Access to Affordable Medicines & Medical Products.

FDA Approves Immunotherapy Regimen Studied by Mayo Clinic for Stage 3 Colon Cancer

The Food and Drug Administration (FDA) has approved the immunotherapy drug atezolizumab in combination with chemotherapy for some patients with stage 3 colon cancer following surgery. The treatment is for patients whose tumors have deficient DNA mismatch repair, or dMMR.

Texas Oncology Expands Cancer Care With New McAllen West Clinic

Texas Oncology celebrated the grand opening of its McAllen West clinic Sept. 29, expanding cancer treatment, diagnostic, and research capabilities in the Rio Grande Valley as the organization continues its presence in the region, spanning more than 40 years.
- Advertisement -